News

Canaccord Genuity Optimizes Tesla's Price Amid Growth Prospects

Canaccord Genuity Optimizes Tesla's Price Amid Growth Prospects

Canaccord Genuity Optimizes Tesla's Price Amid Growth Prospects

Canaccord Genuity has elevated its price target for Tesla (NASDAQ: TSLA) to $404, shifting from a previous target of $298. This decision is underscored by a maintained Buy rating, an encouraging sign even considering the weaker-than-anticipated delivery figures recently reported by Tesla.

The latest information from Canaccord reveals that the new price target is rooted in a projected 40x multiple of the company's 2027E non-GAAP earnings per share (EPS) estimate, projected at $10.11. This marks an increase from the previously applied multiple of approximately 34x based on 2026 EPS estimates. Such analysis demonstrates that Canaccord remains committed to the belief that Tesla’s potential justifies this updated valuation.

The analyst, George Gianarikas, conveyed that the chosen multiple is reasonable when compared to the group of large-cap tech companies that are seen as Tesla's peers, including notable names such as Alphabet, Amazon, Apple, Meta, Microsoft, and Nvidia. His examination indicates that while these companies trade at a median of around 23x 2027E EPS, they collectively show a revenue growth rate significantly less than that of Tesla.

Tesla’s recent delivery reports have indeed shown some shortfalls. The car manufacturer disclosed that it delivered around 495,600 units in the fourth quarter, which represents a 7.1% increase from the previous quarter. However, this result fell below Canaccord's expectation of approximately 533,000 deliveries and was slightly less than the consensus estimate of 498,000. Furthermore, Tesla's production saw a slight decline of 2.2%, totaling around 459,500 units.

Despite these delivery challenges, Canaccord's confidence in Tesla remains firm, primarily driven by expectant product launches scheduled for 2025. The company anticipates a respectable year-over-year growth in unit volume of around 20-30%.

Tesla has a history of invigorating its market presence through the introduction of new vehicles. Analysts note that the excitement generated during product refreshes typically corresponds with increased sales, and this upcoming portfolio refresh is generating enthusiasm among investors.

The report highlights that Tesla has reduced the cost of goods sold per vehicle to $35,100 as of 3Q24, setting a new record low for the company and indicating efficiency improvements which may positively influence profit margins moving forward. Gianarikas noted that while it is difficult to predict the exact impact of new products on mix, the forecast for improving margins in 2025 remains optimistic.

Furthermore, the advancements in Tesla’s Full Self-Driving (FSD) software presence play a vital role in bullish perspectives. Recent updates have received rave reviews from users, which could signify an increase in adoption rates. Analyst Gianarikas mentioned that heightened FSD adoption could enhance Tesla's profit margins and reinforce investor confidence stemming from the company’s substantial investments in artificial intelligence infrastructure.

The energy storage division of Tesla also remains a vibrant segment of the business, with deployments reaching approximately 11.0 GWh in the fourth quarter. This impressive figure represents a sequential increase of 59.4% and a staggering year-over-year growth of 243.5%. The completion of the Shanghai Megafactory in late 2024 sets the stage for production growth anticipated to begin ramping up in 1Q25.

In an intriguing direction, Canaccord emphasizes the potential Tesla possesses within the robotics sector. With 2025 projected as a pivotal year in this industry, the firm is keenly aware of how Tesla is positioned to leverage this emerging market, further supporting its improved earnings multiple.

Through this complete analysis, Canaccord Genuity's revision reflects a continued faith in Tesla's evolution and performance as new technologies and products unfold within its pipeline.

Frequently Asked Questions

What is Canaccord Genuity's new price target for Tesla?

Canaccord Genuity has raised its price target for Tesla to $404 from a previous target of $298.

Why did Canaccord Genuity maintain a Buy rating for Tesla?

Despite weaker delivery numbers, Canaccord maintains the Buy rating based on Tesla's long-term growth potential and upcoming product launches.

How did Tesla's fourth-quarter deliveries compare to estimates?

Tesla's fourth-quarter deliveries totaled around 495,600, falling short of Canaccord's estimate of approximately 533,000.

What improvements has Tesla made in production costs?

Tesla has reduced the cost of goods sold per vehicle to $35,100, which is its lowest figure to date.

What role does Tesla's energy storage sector play in the company's growth?

Tesla's energy storage sector saw a significant increase, with deployments jumping to about 11.0 GWh, showing robust growth in both sequential and year-over-year terms.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 316

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 0

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 291

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Stretch Zone Expands Horizons with Canadian Studio Launch

Updated Category News Views 214

Stretch Zone's Exciting New Chapter in Canada Stretch Zone, a trailblazer in the realm of assisted stretching, has embarked on a significant milestone by opening its first studio in Canada. This new location is not just a store but a powerful symbol of the brand's commitment to enhance flexibility and mobility in communities beyond the United States. The Vision Behind the...

Continue Reading
Eilean Therapeutics Unveils Groundbreaking JAK2 Inhibitor ZE74-0282

Updated Category News Views 585

New Frontiers in JAK2 Inhibition by Eilean Therapeutics Eilean Therapeutics LLC, a pioneering biotechnology company, is set to make waves in cancer treatment with its latest development, ZE74-0282, a wild-type-sparing JAK2-JH2/V617F inhibitor. The company has announced an exciting presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, focusing...

Continue Reading
PodcastOne Extends LadyGang Contract as It Approaches 1000 Episodes

Updated Category News Views 116

PodcastOne Renews its Agreement with LadyGang Podcast PodcastOne, a key player in the podcasting world, is thrilled to announce the renewal of its contract with the immensely popular LadyGang podcast, hosted by Keltie Knight, Becca Tobin, and Jac Vanek. Launched in 2015 on PodcastOne, this engaging podcast has resonated with millions of listeners and is gearing up to...

Continue Reading
BCA Research Warns Upcoming Rate Cuts May Be Insufficient

Updated Category News Views 73

BCA Research Warns Rate Cuts May Arrive Too Late BCA Research has expressed concerns about the upcoming rate cuts, suggesting they might not effectively address a potential recession. The firm points out that the effects of monetary policy often lag, meaning the economy is still grappling with the repercussions of previous tightening measures. Market Sentiments and...

Continue Reading
SOMOS Pilates Nashville: A Vibrant Rebranding Journey

Updated Category News Views 235

SOMOS Pilates Nashville: A Vibrant Rebranding Journey In an inspiring shift, Studio Pilates Nashville has announced its rebranding as SOMOS Pilates Nashville. This transition marks a significant evolution, aimed at celebrating the studio's growth and commitment to community-centered movement practices. Welcoming a New Identity The rebranding initiative reveals more than...

Continue Reading